ZA200106884B - Method for acylating peptides and novel acylating agents. - Google Patents

Method for acylating peptides and novel acylating agents.

Info

Publication number
ZA200106884B
ZA200106884B ZA200106884A ZA200106884A ZA200106884B ZA 200106884 B ZA200106884 B ZA 200106884B ZA 200106884 A ZA200106884 A ZA 200106884A ZA 200106884 A ZA200106884 A ZA 200106884A ZA 200106884 B ZA200106884 B ZA 200106884B
Authority
ZA
South Africa
Prior art keywords
acylating
peptides
novel
agents
acylating agents
Prior art date
Application number
ZA200106884A
Other languages
English (en)
Inventor
Louis Brammer Hansen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of ZA200106884B publication Critical patent/ZA200106884B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
ZA200106884A 1999-03-17 2001-08-21 Method for acylating peptides and novel acylating agents. ZA200106884B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99610019 1999-03-17
EP00910573A EP1163211B1 (en) 1999-03-17 2000-03-16 Method for acylating peptides and proteins

Publications (1)

Publication Number Publication Date
ZA200106884B true ZA200106884B (en) 2002-03-01

Family

ID=26074622

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200106884A ZA200106884B (en) 1999-03-17 2001-08-21 Method for acylating peptides and novel acylating agents.

Country Status (16)

Country Link
EP (2) EP1956000B1 (xx)
CN (1) CN1344248A (xx)
AT (1) ATE409193T1 (xx)
AU (1) AU3273500A (xx)
BR (1) BR0009040A (xx)
CA (1) CA2361830A1 (xx)
CZ (1) CZ20013018A3 (xx)
DE (1) DE60040333D1 (xx)
ES (1) ES2315226T3 (xx)
HU (1) HUP0200297A3 (xx)
IL (1) IL144989A0 (xx)
NO (1) NO20014508D0 (xx)
PL (1) PL351326A1 (xx)
RU (1) RU2001128068A (xx)
WO (1) WO2000055119A1 (xx)
ZA (1) ZA200106884B (xx)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE382057T1 (de) * 2001-06-28 2008-01-15 Novo Nordisk As Stabile formulierung von modifiziertem glp-1
EP1421103B1 (en) * 2001-07-24 2008-10-15 Novo Nordisk A/S Method for making acylated polypeptides
JP2005503141A (ja) * 2001-07-24 2005-02-03 ノボ　ノルディスク　アクティーゼルスカブ アシル化ポリペプチドを作出するための方法
US7595172B2 (en) 2001-07-24 2009-09-29 Novo Nordisk A/S Method for making acylated polypeptides
US20030082671A1 (en) 2001-07-24 2003-05-01 Thomas Hoeg-Jensen Method for making acylated polypeptides
CA2458371A1 (en) 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
WO2004029077A2 (en) * 2002-09-25 2004-04-08 Novo Nordisk A/S Method for producing acylated peptides
US7273921B2 (en) 2002-09-25 2007-09-25 Novo Nordisk A/S Method for producing acylated peptides
WO2004029081A2 (en) * 2002-09-25 2004-04-08 Theratechnologies Inc. Modified glp-1 peptides with increased biological potency
PL1633391T3 (pl) 2003-06-03 2012-03-30 Novo Nordisk As Stabilizowane farmaceutycznie kompozycje peptydowe
BRPI0410972C1 (pt) 2003-06-03 2021-05-25 Novo Nordisk As método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia
CN1812808B (zh) 2003-06-03 2012-07-04 诺沃挪第克公司 稳定化的药物肽组合物
ES2660320T3 (es) 2003-11-20 2018-03-21 Novo Nordisk A/S Formulaciones peptídicas que contienen propilenglicol que son óptimas para la producción y para el uso en dispositivos de inyección
US8710181B2 (en) 2004-08-31 2014-04-29 Novo Nordisk A/S Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
JP5107713B2 (ja) 2004-10-07 2012-12-26 ノヴォ ノルディスク アー／エス 遅延性のエキセンディン−４化合物
RU2413530C9 (ru) 2004-11-12 2021-05-18 Ново Нордиск А/С Стабильные препараты инсулинотропных пептидов
WO2009138488A1 (en) 2008-05-15 2009-11-19 Novo Nordisk A/S Purification of peptides prepared by solid phase synthesis
EP2340049B1 (en) 2008-09-12 2015-11-11 Novo Nordisk A/S Method of acylating a peptide or protein
BRPI0823376A2 (pt) 2008-12-15 2015-06-16 Zealand Pharma As Análagos de glucagon
ES2439499T3 (es) 2008-12-15 2014-01-23 Zealand Pharma A/S Análogos de glucagón
BRPI0823378A2 (pt) 2008-12-15 2019-09-24 Zealand Pharma As análogos de glucagon
BRPI0823377A2 (pt) 2008-12-15 2016-09-27 Zealand Pharma As análogos de glucagon
KR101809024B1 (ko) 2009-07-13 2017-12-14 질랜드 파마 에이/에스 아실화 글루카곤 유사체
CN103003300B (zh) 2010-04-27 2017-06-09 西兰制药公司 Glp‑1受体激动剂和胃泌素的肽缀合物及其用途
AR081975A1 (es) 2010-06-23 2012-10-31 Zealand Pharma As Analogos de glucagon
RU2598273C2 (ru) 2010-06-23 2016-09-20 Ново Нордиск А/С Производные инсулина, содержащие дополнительные дисульфидные связи
MX2012014961A (es) 2010-06-24 2013-02-26 Zealand Pharma As Analogos de glucagon.
EA201390796A1 (ru) 2011-01-20 2014-07-30 Зилэнд Фарма А/С Применение ацилированного аналога глюкагона
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
EP2707713A2 (en) 2011-05-10 2014-03-19 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
US9259477B2 (en) 2011-11-03 2016-02-16 Zealand Pharma A/S GLP-1 receptor agonist peptide gastrin conjugates
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
BR112014027348B1 (pt) 2012-05-03 2022-12-20 Zealand Pharma A/S Compostos agonistas duplos gip-glp-1 e métodos
CN109456400A (zh) 2012-07-23 2019-03-12 西兰制药公司 胰高血糖素类似物
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR20150096684A (ko) 2012-12-21 2015-08-25 사노피 엑센딘-4 유도체
KR102236829B1 (ko) 2013-03-15 2021-04-07 프로타고니스트 테라퓨틱스, 인코포레이티드 헵시딘 유사체 및 이의 용도
EP3010546B1 (en) 2013-06-20 2017-08-09 Novo Nordisk A/S Glp-1 derivatives and uses thereof
KR20160029079A (ko) 2013-07-04 2016-03-14 노보 노르디스크 에이/에스 Glp-1 유사 펩티드의 유도체 및 그것의 사용
PT3057984T (pt) 2013-10-17 2018-10-24 Boehringer Ingelheim Int Análogos de glucagon acilados
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
JP6682432B2 (ja) 2013-11-06 2020-04-15 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
EP3066117B1 (en) 2013-11-06 2019-01-02 Zealand Pharma A/S Glucagon-glp-1-gip triple agonist compounds
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN104558097A (zh) * 2014-05-20 2015-04-29 广东东阳光药业有限公司 肽的酰化方法
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN113563423A (zh) 2014-07-17 2021-10-29 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
US10301371B2 (en) 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
SG11201702553RA (en) 2014-10-01 2017-04-27 Protagonist Therapeutics Inc NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
EP3212218B1 (en) 2014-10-29 2021-06-30 Zealand Pharma A/S Gip agonist compounds and methods
CN106999602B (zh) 2014-11-27 2022-02-01 诺和诺德股份有限公司 Glp-1衍生物及其用途
WO2016097108A1 (en) 2014-12-17 2016-06-23 Novo Nordisk A/S Glp-1 derivatives and uses thereof
SG11201707286UA (en) 2015-03-18 2017-10-30 Zealand Pharma As Amylin analogues
CN107636010B (zh) 2015-04-16 2021-10-01 西兰制药公司 酰化胰高血糖素类似物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
US10787490B2 (en) 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
EP3196206A1 (en) 2016-01-20 2017-07-26 Lonza Ltd Method for preparation of liraglutide
DK3405476T3 (da) 2016-01-20 2024-05-21 Polypeptide Laboratories Holding Ppl Ab Fremgangsmåde til fremstilling af peptider med psWANG linker
EP3205660A1 (en) 2016-02-10 2017-08-16 Polypeptide Laboratories Holding (PPL) AB Method for preparation of peptides with pswang linker
EP3205664A1 (en) 2016-02-11 2017-08-16 Polypeptide Laboratories Holding (PPL) AB Method for preparation of liraglutide using bal linker
US10407468B2 (en) 2016-03-23 2019-09-10 Protagonist Therapeutics, Inc. Methods for synthesizing α4β7 peptide antagonists
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
WO2018083335A1 (en) 2016-11-07 2018-05-11 Novo Nordisk A/S Dchbs-active esters of peg compounds and their use
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
AU2017373651B2 (en) 2016-12-05 2022-03-10 Nuritas Limited Compositions comprising peptide wkdeagkplvk
WO2018103868A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018104561A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
WO2018104558A1 (en) 2016-12-09 2018-06-14 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
PL3474820T3 (pl) 2017-08-24 2024-05-13 Novo Nordisk A/S Kompozycje glp-1 i ich zastosowania
TW201920234A (zh) 2017-09-11 2019-06-01 美商領導醫療有限公司 類鴉片促效劑肽及其用途
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
US11965039B2 (en) 2018-02-27 2024-04-23 Zp Spv 3 K/S Compstatin analogues and their medical uses
WO2020127476A1 (en) 2018-12-19 2020-06-25 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
CN111909073A (zh) * 2019-05-10 2020-11-10 江苏万邦医药科技有限公司 一种制备高纯度脂肪酸衍生物的方法
CA3146390A1 (en) 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CN114630836A (zh) 2019-08-27 2022-06-14 西兰制药第三特殊目的公司 补体抑制素类似物及其医学用途
MX2022002633A (es) 2019-09-03 2022-06-02 Protagonist Therapeutics Inc Mimeticos de hepcidina conjugada.
JP2022550067A (ja) 2019-09-27 2022-11-30 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｅａｃａｍ抗体及びその使用
WO2021123228A1 (en) 2019-12-18 2021-06-24 Krka, D.D., Novo Mesto Pharmaceutical composition comprising glp-1 analogue
MX2022008741A (es) 2020-01-15 2022-10-03 Janssen Biotech Inc Inhibidores de peptidos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
CN115279782A (zh) 2020-01-15 2022-11-01 詹森生物科技公司 白介素-23受体的肽抑制剂及其用于治疗炎性疾病的用途
CA3165359A1 (en) 2020-02-18 2021-07-22 Dorthe Kot Engelund Glp-1 compositions and uses thereof
EP4126003A1 (en) 2020-03-30 2023-02-08 Zealand Pharma A/S Glp-1/glp-2 dual agonists
EP4126004A1 (en) 2020-03-30 2023-02-08 Zealand Pharma A/S Agonist combination
MX2023005994A (es) 2020-11-20 2023-08-11 Janssen Pharmaceutica Nv Composiciones de inhibidores peptidicos del receptor de interleucina-23.
WO2022157747A2 (en) 2021-01-25 2022-07-28 Mylan Ireland Limited Pharmaceutical peptide compositions and methods of preparation thereof
CA3228429A1 (en) 2021-09-03 2023-03-09 Mikkel Askjar Agersnap Dosage regime
WO2024061919A1 (en) 2022-09-19 2024-03-28 Zealand Pharma A/S Combination therapy
WO2024068848A1 (en) 2022-09-28 2024-04-04 Zealand Pharma A/S Methods for treating obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
DE69731105T2 (de) 1996-07-11 2005-11-17 Novo Nordisk A/S Verfahren zur selektiven acetylierung
JP3149958B2 (ja) * 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１誘導体
WO1998008872A1 (en) * 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-2 derivatives
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action

Also Published As

Publication number Publication date
ATE409193T1 (de) 2008-10-15
DE60040333D1 (de) 2008-11-06
EP1956000B1 (en) 2016-10-05
HUP0200297A2 (en) 2002-06-29
CN1344248A (zh) 2002-04-10
WO2000055119A1 (en) 2000-09-21
HUP0200297A3 (en) 2002-09-30
EP1163211A1 (en) 2001-12-19
EP1163211B1 (en) 2008-09-24
IL144989A0 (en) 2002-06-30
EP1956000A1 (en) 2008-08-13
PL351326A1 (en) 2003-04-07
NO20014508L (no) 2001-09-17
NO20014508D0 (no) 2001-09-17
BR0009040A (pt) 2001-12-18
CZ20013018A3 (cs) 2002-02-13
AU3273500A (en) 2000-10-04
RU2001128068A (ru) 2004-02-20
ES2315226T3 (es) 2009-04-01
CA2361830A1 (en) 2000-09-21

Similar Documents

Publication Publication Date Title
IL144989A0 (en) Method for acylating peptides and novel acylating agents
WO1998020133A3 (en) Proteins with enhanced levels of essential amino acids
DE69532996D1 (de) Peptidanaloge des menschlichen basischen myelinproteins
GR3019901T3 (en) Osteoinductive pharmaceutical formulations
HK1021824A1 (en) Compositions and methods for treating infections using analogues of indolicidin
IL128829A0 (en) Improved solid-phase peptide and agent for use in such synthesis
ZA987661B (en) Protein composition and process for isolating a protein composition from a muscle source
AU1232602A (en) Vaccine composition
ID19203A (id) Proses untuk mengisolasi komposisi protein dari sumber otot dan komposisi protein tersebut
ZA9811327B (en) Compositions and methods for altering amino acid content of proteins
HU9200548D0 (en) Improved activity process of recombined proteins
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
IL85020A0 (en) Pancreatic secretory trypsin inhibitor and variants thereof,process expression vector and recombinant host therefor and pharmaceutical compositions containing it
RU94036776A (ru) Домен ингибитора протеазы, днк, вектор, клетка, способ получения ингибитора протеазы, фармацевтическая композиция, применение домена ингибитора протеазы
GB9606040D0 (en) Active peptide
EP0950663A4 (en) USEFUL PROTEIN STABILIZATION AND USEFUL PROTEIN COMPOSITIONS
EP0716591A4 (en) METHODS AND COMPOSITIONS FOR FIXING TAU AND MAP2c PROTEINS
IL95863A0 (en) Anticoagulant peptides and compositions containing them
IL153600A0 (en) TRANSPORT OF PEPTIDES AMONG WHICH C-TERMINAL Erns PEPTIDE AND ANALOGUES THEREOF
ATE113986T1 (de) Verfahren zur herstellung von aprotinin und aprotinin-homologen in hefe.
EP0846950A3 (en) Peptides useful as internal standards for microsequencing and method for their use
NZ511747A (en) Regulatory/unfolding peptides of ezrin
ATE282088T1 (de) Aminopeptidase, welche von bacillus licheniformis abstammt und verfahren zur herstellung von proteinen des natürlichen typs
MX9708930A (es) Alteracion de composiciones aminoacidas en semillas.